argenx account plan
Developing antibody-based medicines
At a glance
argenx is a Dutch-Belgian immunology biotech selling VYVGART, the first approved FcRn blocker: $4.2 billion FY2025 product net sales, 1,863 employees.
argenx SE is a European company with its seat in Amsterdam and its principal offices and R&D in Zwijnaarde, Belgium, that discovers and sells antibody-based medicines for severe autoimmune diseases. Its only marketed product is the VYVGART franchise (efgartigimod), approved for generalized myasthenia gravis (gMG) and CIDP in more than 30 countries and sold mainly in the United States through its own sales force, with Zai Lab as partner in Greater China. FY2025 product net sales were $4.2 billion, up 90%, and profit for the year was $1.3 billion, its first year of operational profitability. It had 1,863 employees at end-2025, outsources manufacturing to Lonza and Fujifilm, and has been led by CEO Karen Massey since May 2026.
Business units
VYVGART franchise (efgartigimod)
$4,151,316 thousand FY2025 product net sales, all product salesThe first-and-only IgG Fc-antibody fragment targeting FcRn, sold as IV, subcutaneous and prefilled syringe versions for gMG, CIDP and ITP in Japan; more than 19,000 patients were treated in 2025. The U.S. label now covers all gMG serotypes, an autoinjector is positioned to launch in 2027, and registrational trials cover myositis, primary ITP, Sjogren's and Graves' disease.
empasiprubart (anti-C2)
A clinical-stage antibody targeting complement C2, in Phase 3 head-to-head against IVIg in MMN (topline in 4Q 2026) and in two Phase 3 CIDP trials (2H 2027); argenx calls it a potential "pipeline-in-a-product".
adimanebart (MuSK agonist)
A first-in-class MuSK agonist antibody to stabilise the neuromuscular junction, with a registrational study in congenital myasthenic syndromes to begin in 2026 and a Phase 2 in SMA ongoing.
Early-stage pipeline and Immunology Innovation Program
Next-generation FcRn molecules ARGX-213 (Phase 3 ready, monthly dosing) and ARGX-124, plus ARGX-121 in IgA nephropathy, ARGX-109, ARGX-118, ARGX-125 and TSP-101; ten molecules are expected in clinical development by end-2026.
Strategic priorities
- Vision 2030
- Treat 50,000 patients, secure 10 labeled indications and advance five pipeline candidates into Phase 3 by 2030.
- More VYVGART patients
- Expand VYVGART through label expansions such as all gMG serotypes and ocular MG, new presentations like the prefilled syringe and a 2027 autoinjector, and myositis as the entry into rheumatology.
- Future of FcRn medicines
- Shape the long-term future of FcRn with next-generation molecules ARGX-213 and ARGX-124, an oral FcRn program, new delivery modalities and combinations.
- Next wave of immunology
- Diversify beyond FcRn, led by empasiprubart, and add novel biology through business development with biotechs as well as academic partners.
- Keep the argenx way
- Teams are organised by indication area rather than functional silos to avoid hierarchy and bureaucracy while the company scales.
Latest results
In H1 2026 (six months to June 30, 2026) VYVGART product net sales were $2,813 million against $1,739 million in H1 2025, and operating profit rose to $887 million from $340 million; profit for the period was $838 million. The United States contributed $2,380 million, Japan $169 million and the rest of the world $247 million. In Q2 2026 alone product net sales were $1.5 billion, up 60% year over year and the 18th consecutive quarter of growth, while combined R&D and SG&A stepped up to $903 million. Cash and cash equivalents were $3,584 million plus $1,600 million of current financial assets at June 30, 2026.
Investments and deals
- Forte Biosciences acquisition
- argenx completed the $2.2 billion acquisition of Forte Biosciences, as cited by PharmaVoice in August 2026.
- R&D spending
- R&D expenses were $1,364,132 thousand in FY2025 (+39%) and $929 million in H1 2026, funding registrational studies of efgartigimod, empasiprubart and adimanebart.
- Manufacturing capacity
- The Fujifilm partnership expanded in 2025 to a North Carolina site; commercial supply commitments with Lonza and Fujifilm total approximately $1.2 billion.
- Commercial build-out
- SG&A grew 30% in 2025 to scale VYVGART commercial operations, and argenx is preparing to expand its field force for a myositis launch.
Challenges and risks
- Single-product dependence
- All product sales come from VYVGART, and competition in gMG and CIDP is intense, with competitors including AstraZeneca, AbbVie, Amgen, Johnson & Johnson and Novartis.
- Customer concentration
- Three U.S. customers represented approximately 72% of product net sales in H1 2026.
- U.S. pricing reform
- IRA Medicare negotiation, inflation rebates, Part D redesign and state price controls are named risks for a business that is mainly U.S.-weighted.
- Exclusivity and biosimilars
- Base regulatory exclusivity is expected until December 2033 in the U.S. and August 2032 in the EU, and EU pharmaceutical reform is likely to shorten baseline market exclusivity.
- Reliance on third parties
- Manufacturing, clinical research and distribution depend on CROs, contract manufacturers and partners such as Zai Lab, with tariff and U.S.-China trade risk.
What leadership says
“Similar to Keytruda, it's a once-in-a-generation asset that acts as a backbone therapy that allows us to build on it.”
“Our strategy in general is that we're not just an FcRn company. Our goal is to become an immunology innovator and transform the lives of immunology patients more broadly.”
“VYVGART has the potential to have a similar impact in rheumatology as it has had in neurology. Autoimmune myositis is our entry point.”
“it has to be novel biology, and it has to be in areas where there is significant unmet patient need.”
Where a supplier can help
- Launch readiness in rheumatology
- The myositis launch, engagement with 650 KOLs and a field force expansion create demand for medical affairs, commercial analytics and HCP engagement services.
- Clinical trial execution
- Multiple registrational readouts and ten molecules in clinic by end-2026 rely on CROs and trial technology, an opening for clinical operations and data vendors.
- Manufacturing and device supply
- Outsourced manufacturing with about $1.2 billion of supply commitments and the 2027 autoinjector launch point to CDMO, fill-finish and device partners.
- Patient access and market access
- U.S. pricing reform and payer coverage of new labels such as seronegative gMG call for market access, reimbursement and patient support services.
- AI for internal operations
- The CEO uses an AI agent daily and argenx runs AI-built innovation dashboards; AI tools that cut reporting overhead fit its fight against bureaucracy.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like argenx?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- argenx SE Annual Report on Form 20-F for the year ended December 31, 2025
- argenx SE is a Dutch European company (seat in Amsterdam, R&D and principal offices in Zwijnaarde, Belgium) that discovers and sells antibody-based immunology medicines; it reports as one business unit and its only marketed product is the VYVGART franchise (efgartigimod, the first approved FcRn blocker).
- FY2025 product net sales were $4.2 billion, up from $2.2 billion in 2024 (+90%); total operating income $4,248,050 thousand; operating profit $1,053,806 thousand versus an operating loss in 2024; profit for the year $1.3 billion (2024: $0.8 billion), its first year of operational profitability.
- Sales are heavily US-weighted: United States $3,533,939 thousand of $4,151,316 thousand; Japan $206,835 thousand; China $67,920 thousand; rest of the world $342,622 thousand. Four U.S. customers account for approximately 78% of product net sales.
- VYVGART reached more than 19,000 patients across gMG, CIDP and ITP (Japan) and three presentations (IV, SC, prefilled syringe); it is approved in more than 30 countries and passed $1 billion of quarterly sales for the first time in Q3 2025.
- Vision 2030: treat 50,000 patients, secure 10 labeled indications and advance five pipeline candidates into Phase 3 by 2030; 2026 priorities are more VYVGART patients, the long-term future of FcRn medicines, and the next wave of immunology innovation.
- Pipeline: efgartigimod in more than ten further autoimmune indications (myositis, primary ITP, Sjogren's, Graves' disease, ocular MG); empasiprubart (anti-C2) in three Phase 3 trials in MMN and CIDP; adimanebart (MuSK agonist) in CMS and SMA; next-generation FcRn molecules ARGX-213 and ARGX-124.
- Balance sheet: $3.5 billion cash and cash equivalents plus $0.9 billion current financial assets at end-2025; total equity $7.3 billion; R&D expenses $1.4 billion; 1,863 employees (789 in the U.S., 565 in Belgium).
- Manufacturing is fully outsourced (Lonza; Fujifilm in Denmark and, from 2025, North Carolina); key risks are competition in gMG/CIDP, biosimilars after exclusivity (to December 2033 in the U.S.), IRA and other U.S. pricing reform, and reliance on third parties.
- Leadership change: COO Karen Massey was put forward to become CEO and co-founder Tim Van Hauwermeiren to become non-executive chair at the 2026 General Meeting.
- argenx Half-Year 2026 Financial Report (unaudited interim report for the six months ended June 30, 2026)
- H1 2026 VYVGART product net sales were $2,813 million versus $1,739 million in H1 2025, a year-over-year increase of $1.1 billion; total operating income $2.9 billion.
- Operating profit $887 million (H1 2025: $340 million); profit for the period $838 million; basic profit per share $13.47 (H1 2025: $6.80).
- R&D expenses $929 million (H1 2025: $642 million) and SG&A $772 million, reflecting multiple registrational studies and the global commercialization of VYVGART.
- By country: United States $2,380 million, Japan $169 million, China $17 million, rest of the world $247 million; three U.S. customers represent approximately 72% of product net sales.
- Cash and cash equivalents $3,584 million plus current financial assets $1,600 million at June 30, 2026; cash flow from operating activities $0.7 billion.
- VYVGART and VYVGART Hytrulo label expanded in the U.S. to all gMG serotypes; autoinjector positioned to launch in 2027; myositis readout expected 3Q 2026, empasiprubart MMN readout 4Q 2026.
- Karen Massey became executive director and CEO and Tim Van Hauwermeiren non-executive chair at the AGM of May 6, 2026.
- Commercial supply commitments with Lonza and Fujifilm total approximately $1.2 billion.
- argenx Q2 2026 Earnings Call Transcript
- CEO Karen Massey: "one of our strongest quarters yet, marking our 18th consecutive quarter of growth"; CFO Karl Gubitz reported Q2 product net sales of $1.5 billion, up 60% year over year and 17% quarter over quarter.
- Regional split given by the CFO: $1.3 billion U.S., $102 million Japan (including a one-off benefit of about $25 million from a distribution-model change), $136 million rest of world, $5 million supply to Zai Lab.
- Combined R&D and SG&A stepped up to $903 million in the quarter; operating profit $494 million (+146% year over year); cash $5.2 billion; net price per patient stable.
- Seronegative gMG launch: payer policies cover about 55% of U.S. commercial lives within 10 weeks, most plans dropping serology testing; the label adds 11,000 addressable MG patients; a halo effect on seropositive prescribing.
- Prefilled syringe: about 80% of Q2 U.S. PFS patients new to VYVGART; repeat prescriber base of more than 5,000 neurologists; autoinjector on schedule for a 2027 launch.
- Myositis is the entry into rheumatology; the filing path is IMNM (no approved therapy, FDA breakthrough designation), with DM analysed separately; argenx is engaging 650 KOLs ahead of a launch.
- empasiprubart MMN Phase 3 is head-to-head against IVIg with non-inferiority as the primary endpoint and superiority as upside.
- Capital allocation: fuel VYVGART, fund the internal pipeline, then business development on novel biology and high unmet need, diversifying beyond FcRn.
- A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act. (PharmaVoice, First 90 Days)
- First interview series piece with Karen Massey after she became CEO in May 2026, succeeding co-founder Tim Van Hauwermeiren, who became chair.
- Massey positions VYVGART as "a once-in-a-generation asset that acts as a backbone therapy", likening it to Keytruda: about 100 diseases could potentially be treated, about 15 indications are studied or planned.
- Next-generation FcRn molecules ARGX-213 and ARGX-124 are meant to widen the indication count further; Vision 2030 is 50,000 patients in 10 approved indications.
- "we're not just an FcRn company": the goal is to become an immunology innovator, sourcing novel biology from its own pipeline, biotechs and academia, "agnostic about the source".
- The article cites H1 2026 VYVGART sales of over $2.8 billion, the completed $2.2 billion acquisition of Forte Biosciences and positive Phase 3 myositis results.
- Organisation: teams are grouped by indication area rather than functional silos, "very actively fighting against the hierarchy and bureaucracy".
- Her stated risks of scaling are arrogance and bureaucracy; she protects "the Argenx way" as a competitive advantage.
- She uses an AI agent daily and the company runs AI-built dashboards for quarterly innovation reviews without manual status reporting.
Questions about argenx
What does argenx do?
argenx discovers and sells antibody-based medicines for severe autoimmune diseases; its marketed product is VYVGART (efgartigimod), the first approved FcRn blocker, for gMG, CIDP and ITP in Japan.
What is argenx's revenue?
FY2025 product net sales were $4.2 billion, up 90%, and H1 2026 product net sales were $2,813 million.
How many employees does argenx have?
argenx had 1,863 employees at end-2025, including 789 in the U.S. and 565 in Belgium.
Who leads argenx?
Karen Massey became CEO in May 2026, succeeding co-founder Tim Van Hauwermeiren, who became non-executive chair; Karl Gubitz is CFO.
What is argenx's strategy?
Under Vision 2030 argenx aims to treat 50,000 patients in 10 labeled indications and bring five candidates into Phase 3, growing VYVGART while diversifying its immunology pipeline beyond FcRn.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)